{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T19:39:11Z","timestamp":1776195551667,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Baudax Bio"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonsteroidal anti\u2010inflammatory drugs (NSAIDs) are effective treatments for pain but may induce bleeding events due to platelet dysfunction associated with inhibition of cyclooxygenase (COX)\u20101 impairing thromboxane production. An intravenous nanocrystal formulation of meloxicam, a COX\u20102 preferential nonsteroidal anti\u2010inflammatory drug, is under development for the treatment of moderate to severe pain. This single\u2010center ex vivo study evaluated the effect of meloxicam intravenous and ketorolac on platelet function in whole blood samples from healthy volunteers. Each whole blood sample was aliquoted to allow analysis using a platelet function analyzer under negative control (untreated), positive control (2 therapeutic ketorolac concentrations), and meloxicam intravenous (1 therapeutic, 3 supratherapeutic concentrations) using both collagen with epinephrine and collagen with adenosine diphosphate reagent cartridges. The platelet function analyzer determines closure time by simulating platelet adhesion and aggregation following vascular injury. The final analysis set included data from 8 subjects. The collagen with adenosine diphosphate analysis (sensitive to thrombocytopathies) showed no significant differences in closure time for meloxicam\u2010 or ketorolac\u2010treated samples and untreated control. The collagen with epinephrine analysis (sensitive to aspirin\u2010induced platelet abnormalities) produced no significant difference in closure time between any meloxicam concentration and untreated control. Ketorolac was associated with significantly longer closure times vs untreated control at both the 2.5\u2010 and 5\u2010\u00b5g\/mL concentrations (<jats:italic>P<\/jats:italic> = .003 and .0257, respectively) and vs meloxicam at several concentrations. Similar results were observed when all analyzed samples were included. Meloxicam intravenous had no significant effect on closure times at therapeutic or supratherapeutic concentrations in this ex vivo study.<\/jats:p>","DOI":"10.1002\/cpdd.772","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T10:06:18Z","timestamp":1579601178000},"page":"841-848","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers"],"prefix":"10.1002","volume":"9","author":[{"given":"Jonathan S.","family":"Jahr","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA Ronald Reagan UCLA Medical Center\/UCLA Health  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Searle","sequence":"additional","affiliation":[{"name":"PRA Health Sciences  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart","family":"McCallum","sequence":"additional","affiliation":[{"name":"Baudax Bio (formerly Recro Pharma, Inc.)  Malvern Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Mack","sequence":"additional","affiliation":[{"name":"Baudax Bio (formerly Recro Pharma, Inc.)  Malvern Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Minger","sequence":"additional","affiliation":[{"name":"Baudax Bio (formerly Recro Pharma, Inc.)  Malvern Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Freyer","sequence":"additional","affiliation":[{"name":"Baudax Bio (formerly Recro Pharma, Inc.)  Malvern Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[{"name":"Clinical Statistics Consulting  Blue Bell Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Hobson","sequence":"additional","affiliation":[{"name":"Baudax Bio (formerly Recro Pharma, Inc.)  Malvern Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization. WHO's cancer pain ladder for adults.https:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/. Accessed December 19 2018."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110814"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04050.x"},{"issue":"3","key":"e_1_2_10_5_1","first-page":"247","article-title":"Anti\u2010inflammatory and side effects of cyclooxygenase inhibitors","volume":"59","author":"Suleyman H","year":"2007","journal-title":"Pharmacol Rep"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27291"},{"issue":"6","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.hco.0000245740.85829.4f","article-title":"Cyclooxygenase\u20102 inhibitors and cardiovascular risk","volume":"21","author":"Solomon SD","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200222120-00001"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.12.2117"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta12110"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1058"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S149879"},{"issue":"10","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/AJP.0000000000000609","article-title":"Efficacy and safety of intravenous meloxicam in patients with moderate\u2010to\u2010severe pain following bunionectomy: a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"34","author":"Pollak R","year":"2018","journal-title":"Clin J Pain"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.666"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000003920"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000001846"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.97"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1997.33.10.451138"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223060-00003"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-49798-5.00013-9"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.03.003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2014.04.130227"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1145254"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-995840"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2011-100265"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152312803476255"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.13.7563"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1997.tb04657.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2000.440113.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04286.x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650627"},{"issue":"6","key":"e_1_2_10_32_1","first-page":"1176","article-title":"Intravenous ketorolac tromethamine worsens platelet function during knee arthroscopy under spinal anesthesia","volume":"82","author":"Thwaites BK","year":"1996","journal-title":"Anesth Analg"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199507000-00024"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2014.03.043"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127002401102795"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.a101063"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.458"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01771.x"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T15:29:09Z","timestamp":1693754949000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/cpdd.772"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.772","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"2019-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}